• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
  

PubMed=8324732
Brunner N., Frandsen T.L., Holst-Hansen C., Bei M., Thompson E.W., Wakeling A.E., Lippman M.E., Clarke R.
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.
Cancer Res. 53:3229-3232(1993)

PubMed=8380254
Brunner N., Boulay V., Fojo A., Freter C.E., Lippman M.E., Clarke R.
Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications.
Cancer Res. 53:283-290(1993)

PubMed=8380760; DOI=10.1007/BF00880062
Thompson E.W., Brunner N., Torri J., Johnson M.D., Boulay V., Wright A., Lippman M.E., Steeg P.S., Clarke R.
The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells.
Clin. Exp. Metastasis 11:15-26(1993)